Health committee  We recently published an updated study that looked at where Canadian generic prices are, relative to international levels, and I can say there is some good news on that front, in that the efforts of the pan-Canadian Pharmaceutical Alliance have closed some of those gaps. The rep

Health committee  There are differences, certainly, from the federal regulator perspective as to how we look at prices. That's one of the reasons that we are looking at framework modernization and examining the best practices internationally. I can tell you, for example, that one of the things w

Health committee  One of the things I want to caution you on in doing these international price comparisons is that every country has gone to an approach that makes it difficult to compare prices, if you will, directly. Every country is engaging in contracting in non-transparent negotiations. When

Health committee  Some countries have mandated their manufacturers to provide this data to them. When they look at a price of a particular product in Germany, for example, they have regulations in place that compel the manufacturer to disclose those rebates. That's one of the areas that is of grea

Health committee  If I could just add, a lot of the high-cost drugs are actually being realized in areas like biologics, oncology drugs, specialty drugs, expensive drugs for rare diseases. We are seeing an unprecedented amount of new drugs that are coming onto international markets at price tags t

Health committee  Mr. Chair, members of the committee, good afternoon. Thank you for the invitation to appear before you today. My name is Tanya Potashnik, and I'm the director of policy and economic analysis at the PMPRB. With me today I have my colleague, Guillaume Couillard, who is the direct